Last 12 months
Inside the activity.
0 purchase rows · 9 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 4 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 4 |
| Jul 2026 | 0 | 1 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 25, 2022 Filed Jul 27, 2022 22:42 UTC |
Metzger Michael ADirector · Chief Executive Officer
|
Exercise / conversionStock Options (Right to buy) · Derivative | 19,764 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-22-005761 · primarydocument.xml · derivative · entry 5 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 19,764 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vests in 48 successive equal monthly installments measured from 02/06/2019. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 22:42 UTC |
Metzger Michael ADirector · Chief Executive Officer
|
SaleCommon Stock | 11,838 | $21.06 | $249,253.83 |
DisclosureSEC source: 0001562180-22-005761 · primarydocument.xml · nonDerivative · entry 4 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 670,466 options to purchase shares of common stock that are vested and immediately exercisable and a total of 539,063 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $21.00 to $21.16. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 22:42 UTC |
Metzger Michael ADirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 11,838 | $6.38 | $75,526.44 |
DisclosureSEC source: 0001562180-22-005761 · primarydocument.xml · nonDerivative · entry 3 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,497 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 22:42 UTC |
Metzger Michael ADirector · Chief Executive Officer
|
SaleCommon Stock | 19,764 | $21.06 | $416,138.93 |
DisclosureSEC source: 0001562180-22-005761 · primarydocument.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 670,466 options to purchase shares of common stock that are vested and immediately exercisable and a total of 539,063 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $21.00 to $21.16. Read SEC document |
| July 25, 2022 Filed Jul 27, 2022 22:42 UTC |
Metzger Michael ADirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 19,764 | $6.38 | $126,094.32 |
DisclosureSEC source: 0001562180-22-005761 · primarydocument.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,423 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 21:51 UTC |
Metzger Michael ADirector · Chief Executive Officer
|
Exercise / conversionStock Options (Right to buy) · Derivative | 100 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-22-005637 · primarydocument.xml · derivative · entry 6 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 100 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vests periodically upon the Issuer achieving certain milestones. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 21:51 UTC |
Metzger Michael ADirector · Chief Executive Officer
|
SaleCommon Stock | 100 | $21.00 | $2,100.00 |
DisclosureSEC source: 0001562180-22-005637 · primarydocument.xml · nonDerivative · entry 4 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 702,068 options to purchase shares of common stock that are vested and immediately exercisable and a total of 554,172 options to purchase shares of common stock that have not yet vested. Read SEC document |
| July 07, 2022 Filed Jul 8, 2022 21:51 UTC |
Metzger Michael ADirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 100 | $6.38 | $638.00 |
DisclosureSEC source: 0001562180-22-005637 · primarydocument.xml · nonDerivative · entry 3 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,759 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:51 UTC |
Metzger Michael ADirector · Chief Executive Officer
|
Exercise / conversionStock Options (Right to buy) · Derivative | 15,009 | $0.00 Strike: $6.38 | $0.00 |
DisclosureSEC source: 0001562180-22-005637 · primarydocument.xml · derivative · entry 5 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,009 shares Expires 2029-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option vests periodically upon the Issuer achieving certain milestones. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:51 UTC |
Metzger Michael ADirector · Chief Executive Officer
|
SaleCommon Stock | 15,009 | $21.07 | $316,307.17 |
DisclosureSEC source: 0001562180-22-005637 · primarydocument.xml · nonDerivative · entry 2 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,659 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 702,068 options to purchase shares of common stock that are vested and immediately exercisable and a total of 554,172 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $21.00 to $21.25. Read SEC document |
| July 06, 2022 Filed Jul 8, 2022 21:51 UTC |
Metzger Michael ADirector · Chief Executive Officer
|
Exercise / conversionCommon Stock | 15,009 | $6.38 | $95,757.42 |
DisclosureSEC source: 0001562180-22-005637 · primarydocument.xml · nonDerivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,668 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:09 UTC |
Morrison BriggsDirector · President, Head of R&D
|
Exercise / conversionStock Options (Right to buy) · Derivative | 62,292 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-22-005475 · primarydocument.xml · derivative · entry 3 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 62,292 shares Expires 2025-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: This option is fully vested. Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:09 UTC |
Morrison BriggsDirector · President, Head of R&D
|
SaleCommon Stock | 62,292 | $19.00 | $1,183,429.65 |
DisclosureSEC source: 0001562180-22-005475 · primarydocument.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,836 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,200,616 options to purchase shares of common stock that are vested and immediately exercisable and a total of 397,792 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $18.61 to $19.38 Read SEC document |
| July 01, 2022 Filed Jul 5, 2022 20:09 UTC |
Morrison BriggsDirector · President, Head of R&D
|
Exercise / conversionCommon Stock | 62,292 | $7.20 | $448,502.40 |
DisclosureSEC source: 0001562180-22-005475 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,128 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 20:12 UTC |
Goldan Keith A.Chief Financial Officer
|
GrantStock Options (Right to buy) · Derivative | 230,000 | $15.60 Strike: $15.60 | $3,588,000.00 |
DisclosureSEC source: 0001562180-22-005117 · primarydocument.xml · derivative · entry 2 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 230,000 Underlying: Common Stock · 230,000 shares Expires 2032-06-13 F2 · derivative.exercise_date: Twenty five percent (25%) of the total number of shares underlying the option shall vest on June 13, 2023, and one-thirty-sixth (1/36th) of the remaining shares underlying the option shall vest monthly thereafter on the last day of each month, subject to the reporting person's continuous service on the relevant vesting dates. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 20:12 UTC |
Goldan Keith A.Chief Financial Officer
|
GrantCommon Stock | 3,205 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-005117 · primarydocument.xml · nonDerivative · entry 1 Goldan Keith A. · CIK 0001495411 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,205 F1 · shares: Award of Restricted Stock Units that vest 50% of the shares on June 13, 2023 and the remaining 50% of the shares on June 13, 2024. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 20:05 UTC |
Morrison BriggsDirector · President, Head of R&D
|
Exercise / conversionStock Options (Right to buy) · Derivative | 3,128 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001562180-22-003223 · primarydocument.xml · derivative · entry 8 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,128 shares Expires 2025-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option is fully vested. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 20:05 UTC |
Morrison BriggsDirector · President, Head of R&D
|
SaleCommon Stock | 3,128 | $18.29 | $57,219.88 |
DisclosureSEC source: 0001562180-22-003223 · primarydocument.xml · nonDerivative · entry 6 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,836 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,221,283 options to purchase shares of common stock that are vested and immediately exercisable and a total of 439,417 options to purchase shares of common stock that have not yet vested. F5 · price: The sale prices ranged from $17.75 to $19.17. Read SEC document |
| April 04, 2022 Filed Apr 5, 2022 20:05 UTC |
Morrison BriggsDirector · President, Head of R&D
|
Exercise / conversionCommon Stock | 3,128 | $10.90 | $34,095.20 |
DisclosureSEC source: 0001562180-22-003223 · primarydocument.xml · nonDerivative · entry 5 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 04, 2022 Filed Apr 13, 2022 20:09 UTC Amendment |
Morrison BriggsDirector · President, Head of R&D
|
Exercise / conversionStock Options (Right to buy) · Derivative | 3,128 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-22-003383 · primarydocument.xml · derivative · entry 4 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,128 shares Expires 2025-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person is not reporting any new transactions in this filing. Amendment filed to correct previously filed Form that contained an incorrect option exercise price and expiration date. F2 · derivative.exercise_date: This option is fully vested. F1 · derivative.expiration_date: The Reporting Person is not reporting any new transactions in this filing. Amendment filed to correct previously filed Form that contained an incorrect option exercise price and expiration date. Read SEC document |
| April 04, 2022 Filed Apr 13, 2022 20:09 UTC Amendment |
Morrison BriggsDirector · President, Head of R&D
|
Exercise / conversionCommon Stock | 3,128 | $7.20 | $22,521.60 |
DisclosureSEC source: 0001562180-22-003383 · primarydocument.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,964 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person is not reporting any new transactions in this filing. Amendment filed to correct previously filed Form that contained an incorrect option exercise price and expiration date. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC |
Morrison BriggsDirector · President, Head of R&D
|
Exercise / conversionStock Options (Right to buy) · Derivative | 70,545 | $0.00 Strike: $10.90 | $0.00 |
DisclosureSEC source: 0001562180-22-003223 · primarydocument.xml · derivative · entry 7 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,545 shares Expires 2025-09-09 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_date: This option is fully vested. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC |
Morrison BriggsDirector · President, Head of R&D
|
SaleCommon Stock | 70,545 | $17.46 | $1,231,567.56 |
DisclosureSEC source: 0001562180-22-003223 · primarydocument.xml · nonDerivative · entry 4 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,836 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,221,283 options to purchase shares of common stock that are vested and immediately exercisable and a total of 439,417 options to purchase shares of common stock that have not yet vested. F4 · price: The sale prices ranged from $17.18 to $17.69. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC |
Morrison BriggsDirector · President, Head of R&D
|
Exercise / conversionCommon Stock | 70,545 | $10.90 | $768,940.50 |
DisclosureSEC source: 0001562180-22-003223 · primarydocument.xml · nonDerivative · entry 3 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC |
Morrison BriggsDirector · President, Head of R&D
|
SaleCommon Stock | 24,500 | $17.44 | $427,314.30 |
DisclosureSEC source: 0001562180-22-003223 · primarydocument.xml · nonDerivative · entry 2 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,836 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,221,283 options to purchase shares of common stock that are vested and immediately exercisable and a total of 439,417 options to purchase shares of common stock that have not yet vested. F3 · price: The sale prices ranged from $17.19 to $17.66. Read SEC document |
| April 01, 2022 Filed Apr 5, 2022 20:05 UTC |
Morrison BriggsDirector · President, Head of R&D
|
SaleCommon Stock | 6,000 | $17.44 | $104,633.40 |
DisclosureSEC source: 0001562180-22-003223 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,336 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 1,221,283 options to purchase shares of common stock that are vested and immediately exercisable and a total of 439,417 options to purchase shares of common stock that have not yet vested. F2 · price: The sale prices ranged from $17.21 to $17.62. Read SEC document |
| April 01, 2022 Filed Apr 13, 2022 20:09 UTC Amendment |
Morrison BriggsDirector · President, Head of R&D
|
Exercise / conversionStock Options (Right to buy) · Derivative | 70,545 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-22-003383 · primarydocument.xml · derivative · entry 3 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 70,545 shares Expires 2025-06-30 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Reporting Person is not reporting any new transactions in this filing. Amendment filed to correct previously filed Form that contained an incorrect option exercise price and expiration date. F2 · derivative.exercise_date: This option is fully vested. F1 · derivative.expiration_date: The Reporting Person is not reporting any new transactions in this filing. Amendment filed to correct previously filed Form that contained an incorrect option exercise price and expiration date. Read SEC document |
| April 01, 2022 Filed Apr 13, 2022 20:09 UTC Amendment |
Morrison BriggsDirector · President, Head of R&D
|
Exercise / conversionCommon Stock | 70,545 | $7.20 | $507,924.00 |
DisclosureSEC source: 0001562180-22-003383 · primarydocument.xml · nonDerivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,381 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Reporting Person is not reporting any new transactions in this filing. Amendment filed to correct previously filed Form that contained an incorrect option exercise price and expiration date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 21:24 UTC |
Madigan CatherineChief Medical Officer
|
GrantStock Options (Right to buy) · Derivative | 180,000 | $16.06 Strike: $16.06 | $2,890,800.00 |
DisclosureSEC source: 0001562180-22-002258 · primarydocument.xml · derivative · entry 1 Madigan Catherine · CIK 0001914577 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2032-03-01 F1 · derivative.exercise_date: Twenty five percent (25%) of the total number of shares underlying the option shall vest on March 1, 2023, and one-thirty-sixth (1/36th) of the remaining shares underlying the option shall vest monthly thereafter on the last day of each month, subject to the reporting person's continuous service on the relevant vesting dates. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 22:29 UTC |
Jarrett JenniferDirector
|
GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001071 · primarydocument.xml · nonDerivative · entry 1 Jarrett Jennifer · CIK 0001671311 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 17:30 UTC |
Podlesak DennisDirector
|
GrantCommon Stock | 32,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001076 · primarydocument.xml · nonDerivative · entry 1 Podlesak Dennis · CIK 0001314595 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,763 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 22:30 UTC |
Katkin KeithDirector
|
GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001074 · primarydocument.xml · nonDerivative · entry 1 Katkin Keith · CIK 0001314596 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 17:30 UTC |
Legault PierreDirector
|
GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001073 · primarydocument.xml · nonDerivative · entry 1 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 22:33 UTC |
Metzger Michael ADirector · Chief Executive Officer
|
GrantStock Options (Right to buy) · Derivative | 325,000 | $15.79 Strike: $15.79 | $5,131,750.00 |
DisclosureSEC source: 0001562180-22-001081 · primarydocument.xml · derivative · entry 1 Metzger Michael A · CIK 0001507220 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 325,000 Underlying: Common Stock · 325,000 shares Expires 2032-02-02 F1 · derivative.exercise_date: The securities awarded on 02/02/2022 were in the form of stock options issued pursuant to the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan. Options to purchase 245,000 shares of common stock shall vest in 48 successive equal monthly installments measured from 02/02/2022. Options to purchase 80,000 shares of common stock shall vest periodically upon the Issuer achieving certain milestones. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 22:32 UTC |
Morrison BriggsDirector · President, Head of R&D
|
GrantStock Options (Right to buy) · Derivative | 160,000 | $15.79 Strike: $15.79 | $2,526,400.00 |
DisclosureSEC source: 0001562180-22-001080 · primarydocument.xml · derivative · entry 1 Morrison Briggs · CIK 0001654430 · Director · President, Head of R&D 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,000 Underlying: Common Stock · 160,000 shares Expires 2032-02-02 F1 · derivative.exercise_date: The securities awarded on 02/02/2022 were in the form of stock options issued pursuant to the Syndax Pharmaceuticals, Inc. 2015 Omnibus Incentive Plan. Options to purchase 100,000 shares of common stock shall vest in 48 successive equal monthly installments measured from 02/02/2022. Options to purchase 60,000 shares of common stock shall vest periodically upon the Issuer achieving certain milestones. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 22:32 UTC |
Ordentlich PeterChief Scientific Officer
|
GrantStock Options (Right to buy) · Derivative | 80,000 | $15.79 Strike: $15.79 | $1,263,200.00 |
DisclosureSEC source: 0001562180-22-001079 · primarydocument.xml · derivative · entry 3 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2032-02-02 F2 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 22:31 UTC |
Meyers Michael L.SVP, Chief Medical Officer
|
GrantStock Options (Right to buy) · Derivative | 17,350 | $15.79 Strike: $15.79 | $273,956.50 |
DisclosureSEC source: 0001562180-22-001078 · primarydocument.xml · derivative · entry 2 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,350 Underlying: Common Stock · 17,350 shares Expires 2032-02-02 F2 · derivative.exercise_date: 1/23rd of the shares subject to the option shall vest monthly over a two-year period. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 22:31 UTC |
Nolte AlexanderChief Accounting Officer
|
GrantStock Options (Right to buy) · Derivative | 30,000 | $15.79 Strike: $15.79 | $473,700.00 |
DisclosureSEC source: 0001562180-22-001077 · primarydocument.xml · derivative · entry 3 Nolte Alexander · CIK 0001891979 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-02-02 F2 · derivative.exercise_date: 1/48th of the shares subject to the option shall vest monthly over a four-year period. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 22:29 UTC |
Egros FabriceDirector
|
GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001072 · primarydocument.xml · nonDerivative · entry 1 Egros Fabrice · CIK 0001597085 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 22:29 UTC |
Meury WilliamDirector
|
GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001070 · primarydocument.xml · nonDerivative · entry 1 Meury William · CIK 0001536778 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| February 02, 2022 Filed Feb 3, 2022 22:28 UTC |
Huber Martin H. Jr.Director
|
GrantCommon Stock | 16,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001562180-22-001069 · primarydocument.xml · nonDerivative · entry 1 Huber Martin H. Jr. · CIK 0001653276 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F1 · shares: Award of Restricted Stock Units that vests one year from the date of grant. The shares underlying such Restricted Stock Units will not be delivered to the Reporting Person and may not be transferred or sold until the earlier of a separation from service, death, disability or change in control. Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:32 UTC |
Ordentlich PeterChief Scientific Officer
|
SaleCommon Stock | 1,412 | $16.65 | $23,509.80 |
DisclosureSEC source: 0001562180-22-001079 · primarydocument.xml · nonDerivative · entry 2 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| February 01, 2022 Filed Feb 3, 2022 22:31 UTC |
Nolte AlexanderChief Accounting Officer
|
SaleCommon Stock | 968 | $16.65 | $16,117.20 |
DisclosureSEC source: 0001562180-22-001077 · primarydocument.xml · nonDerivative · entry 2 Nolte Alexander · CIK 0001891979 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 22:32 UTC |
Ordentlich PeterChief Scientific Officer
|
OtherCommon Stock | 1,412 | $12.39 | $17,494.68 |
DisclosureSEC source: 0001562180-22-001079 · primarydocument.xml · nonDerivative · entry 1 Ordentlich Peter · CIK 0001594274 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,412 F1 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,412 shares by the Reporting Person on 01/31/2022 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 22:31 UTC |
Meyers Michael L.SVP, Chief Medical Officer
|
OtherCommon Stock | 1,714 | $12.39 | $21,236.46 |
DisclosureSEC source: 0001562180-22-001078 · primarydocument.xml · nonDerivative · entry 1 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 23,280 F1 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 1,715 shares by the Reporting Person on 1/31/22 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| January 31, 2022 Filed Feb 3, 2022 22:31 UTC |
Nolte AlexanderChief Accounting Officer
|
OtherCommon Stock | 968 | $12.39 | $11,993.52 |
DisclosureSEC source: 0001562180-22-001077 · primarydocument.xml · nonDerivative · entry 1 Nolte Alexander · CIK 0001891979 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 968 F1 · kind: The Reporting Person is voluntarily filing this Form 4 to report the acquisition of 968 shares by the Reporting Person on 01/31/2022 pursuant to the Issuer's Employee Stock Purchase Plan. Read SEC document |
| December 30, 2021 Filed Jan 3, 2022 21:03 UTC |
Meyers Michael L.SVP, Chief Medical Officer
|
Exercise / conversionStock Options (Right to buy) · Derivative | 5,900 | $0.00 Strike: $8.77 | $0.00 |
DisclosureSEC source: 0001562180-22-000035 · primarydocument.xml · derivative · entry 2 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,900 shares Expires 2027-02-06 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 30, 2021 Filed Jan 3, 2022 21:03 UTC |
Meyers Michael L.SVP, Chief Medical Officer
|
Exercise / conversionCommon Stock | 5,900 | $8.77 | $51,743.00 |
DisclosureSEC source: 0001562180-22-000035 · primarydocument.xml · nonDerivative · entry 1 Meyers Michael L. · CIK 0001664204 · SVP, Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,566 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The Reporting Person is filing this Form 4 to report the acquisition of shares by the Reporting Person pursuant to the exercise of a stock option grant. There are no sales to report in this filing. Read SEC document |
| December 22, 2021 Filed Dec 22, 2021 18:25 UTC |
Legault PierreDirector
|
Exercise / conversionStock Options (Right to buy) · Derivative | 24,000 | $0.00 Strike: $7.88 | $0.00 |
DisclosureSEC source: 0001562180-21-007866 · primarydocument.xml · derivative · entry 6 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,000 shares Expires 2029-06-10 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: This option is fully vested. Read SEC document |
| December 22, 2021 Filed Dec 22, 2021 18:25 UTC |
Legault PierreDirector
|
SaleCommon Stock | 24,000 | $22.01 | $528,206.40 |
DisclosureSEC source: 0001562180-21-007866 · primarydocument.xml · nonDerivative · entry 4 Legault Pierre · CIK 0001391045 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 16,000 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person. Following the sales reported in this Form 4, the Reporting Person has a total of 63,000 options to purchase shares of common stock that are vested and immediately exercisable and there are no options to purchase shares of common stock that have not yet vested. F3 · price: The sale prices ranged from $22.00 to $22.02. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.